Search results
Results from the WOW.Com Content Network
Regeneron Pharmaceuticals (NAS: REGN) has gained Food and Drug Administration approval of its third drug, Zaltrap, which treats metastatic colorectal cancer. Three approvals in four years is no ...
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...
(Reuters) -Regeneron Pharmaceuticals said on Friday the U.S. health regulator approved its drug to treat a rare blood disease. The drug pozelimab, branded as Veopoz, would treat CHAPLE disease in ...
(Reuters) -The U.S. Food and Drug Administration (FDA) on Monday approved two close copies of Regeneron Pharmaceuticals' Eylea, its first-ever clearance to biosimilar versions of the blockbuster ...
The FDA granted the approval of Inmazeb to Regeneron Pharmaceuticals with an indication for the treatment of infection caused by Zaire ebolavirus in October 2020. [ 2 ] [ 6 ] The drug has also received orphan drug designation from the European Medicines Agency .
[1] [2] It was developed by Regeneron Pharmaceuticals. [1] The most common side effects include cytokine release syndrome, infections, neutropenia, pyrexia (fever), anemia, thrombocytopenia, and diarrhea. [1] Odronextamab was approved for medical use in the European Union in August 2024. [1] [2]
A longer dosing gap for the drug could help Regeneron take on rival Roche's Vabysmo and also help soften the blow from incoming cheaper copycat drugs, analysts said. Shares of Regeneron rose 1.7% ...
Regeneron was seeking regulatory approval of its therapy, linvoseltamab, in patients with multiple myeloma whose cancer has returned or worsened after at least three prior lines of treatment. The ...